Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt 89.44
ENZ's Cash-to-Debt is ranked higher than
67% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ENZ: 89.44 )
Ranked among companies with meaningful Cash-to-Debt only.
ENZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: N/A Max: No Debt
Current: 89.44
Equity-to-Asset 0.83
ENZ's Equity-to-Asset is ranked higher than
83% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ENZ: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.86 Max: 0.97
Current: 0.83
0.01
0.97
Interest Coverage 340.01
ENZ's Interest Coverage is ranked higher than
58% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ENZ: 340.01 )
Ranked among companies with meaningful Interest Coverage only.
ENZ' s Interest Coverage Range Over the Past 10 Years
Min: 340.01  Med: No Debt Max: No Debt
Current: 340.01
Piotroski F-Score: 7
Altman Z-Score: 12.06
Beneish M-Score: -2.23
WACC vs ROIC
11.22%
131.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 30.92
ENZ's Operating Margin % is ranked higher than
96% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ENZ: 30.92 )
Ranked among companies with meaningful Operating Margin % only.
ENZ' s Operating Margin % Range Over the Past 10 Years
Min: -39.63  Med: -19.63 Max: 45.73
Current: 30.92
-39.63
45.73
Net Margin % 29.83
ENZ's Net Margin % is ranked higher than
98% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ENZ: 29.83 )
Ranked among companies with meaningful Net Margin % only.
ENZ' s Net Margin % Range Over the Past 10 Years
Min: -38.09  Med: -16.58 Max: 44.06
Current: 29.83
-38.09
44.06
ROE % 42.19
ENZ's ROE % is ranked higher than
95% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ENZ: 42.19 )
Ranked among companies with meaningful ROE % only.
ENZ' s ROE % Range Over the Past 10 Years
Min: -56.99  Med: -16.22 Max: 68.53
Current: 42.19
-56.99
68.53
ROA % 32.40
ENZ's ROA % is ranked higher than
99% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ENZ: 32.40 )
Ranked among companies with meaningful ROA % only.
ENZ' s ROA % Range Over the Past 10 Years
Min: -43.97  Med: -13.85 Max: 50.26
Current: 32.4
-43.97
50.26
ROC (Joel Greenblatt) % 260.42
ENZ's ROC (Joel Greenblatt) % is ranked higher than
97% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ENZ: 260.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -230.98  Med: -98.58 Max: 330.82
Current: 260.42
-230.98
330.82
3-Year Revenue Growth Rate -2.30
ENZ's 3-Year Revenue Growth Rate is ranked lower than
70% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ENZ: -2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.7  Med: 5.3 Max: 28.9
Current: -2.3
-15.7
28.9
GuruFocus has detected 4 Warning Signs with Enzo Biochem Inc $ENZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZ's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENZ Guru Trades in Q1 2016

Jim Simons 1,449,900 sh (+15.71%)
» More
Q2 2016

ENZ Guru Trades in Q2 2016

Jim Simons 1,866,981 sh (+28.77%)
» More
Q3 2016

ENZ Guru Trades in Q3 2016

Jim Simons 1,957,368 sh (+4.84%)
» More
Q4 2016

ENZ Guru Trades in Q4 2016

Jim Simons 1,965,500 sh (+0.42%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:NVDQ, NAS:OXFD, NAS:LNTH, NYSE:NVTA, NAS:NTRA, NAS:PACB, NAS:ONVO, NAS:SRDX, NYSE:ARA, NAS:RDNT, OTCPK:BMLIF, NAS:MGEN, NAS:NRCIA, NAS:VIVO, OTCPK:EPLYF, NAS:QTNT, OTCPK:CBIS, NAS:FLGT, NAS:NEO, AMEX:SENS » details
Traded in other countries:EZB.Germany,
Headquarter Location:USA
Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.

Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. The Company develops, manufactures and sells its proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. The Enzo Clinical Labs is a clinical reference laboratory provides clinical services to a physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. The Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. It owns or license 314 patents relating to products, methods and procedures resulting from its internal or sponsored research projects. The Company distributes its life science products internationally through a network of distributors. It competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The Company is subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste.

Ratios

vs
industry
vs
history
PE Ratio 12.86
ENZ's PE Ratio is ranked higher than
89% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. ENZ: 12.86 )
Ranked among companies with meaningful PE Ratio only.
ENZ' s PE Ratio Range Over the Past 10 Years
Min: 5.25  Med: 11.32 Max: 34.86
Current: 12.86
5.25
34.86
PE Ratio without NRI 12.86
ENZ's PE Ratio without NRI is ranked higher than
88% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. ENZ: 12.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
ENZ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.25  Med: 11.32 Max: 34.86
Current: 12.86
5.25
34.86
Price-to-Owner-Earnings 16.03
ENZ's Price-to-Owner-Earnings is ranked higher than
87% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ENZ: 16.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ENZ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.94  Med: 12.45 Max: 31.48
Current: 16.03
4.94
31.48
PB Ratio 4.51
ENZ's PB Ratio is ranked lower than
60% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ENZ: 4.51 )
Ranked among companies with meaningful PB Ratio only.
ENZ' s PB Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.94 Max: 7.17
Current: 4.51
0.85
7.17
PS Ratio 3.78
ENZ's PS Ratio is ranked higher than
50% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ENZ: 3.78 )
Ranked among companies with meaningful PS Ratio only.
ENZ' s PS Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.04 Max: 13.21
Current: 3.78
0.56
13.21
Price-to-Free-Cash-Flow 13.86
ENZ's Price-to-Free-Cash-Flow is ranked higher than
79% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ENZ: 13.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.59  Med: 10.76 Max: 22.18
Current: 13.86
4.59
22.18
Price-to-Operating-Cash-Flow 13.25
ENZ's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ENZ: 13.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.45  Med: 10.2 Max: 18.48
Current: 13.25
4.45
18.48
EV-to-EBIT 9.71
ENZ's EV-to-EBIT is ranked higher than
92% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ENZ: 9.71 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -64  Med: -7.1 Max: 32.4
Current: 9.71
-64
32.4
EV-to-EBITDA 8.69
ENZ's EV-to-EBITDA is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ENZ: 8.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.1  Med: -8.8 Max: 75.2
Current: 8.69
-42.1
75.2
Current Ratio 4.95
ENZ's Current Ratio is ranked higher than
76% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ENZ: 4.95 )
Ranked among companies with meaningful Current Ratio only.
ENZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 6.54 Max: 33.9
Current: 4.95
0.2
33.9
Quick Ratio 4.54
ENZ's Quick Ratio is ranked higher than
78% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ENZ: 4.54 )
Ranked among companies with meaningful Quick Ratio only.
ENZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 6.28 Max: 33.15
Current: 4.54
0.17
33.15
Days Inventory 44.72
ENZ's Days Inventory is ranked higher than
63% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ENZ: 44.72 )
Ranked among companies with meaningful Days Inventory only.
ENZ' s Days Inventory Range Over the Past 10 Years
Min: 44.72  Med: 60.2 Max: 75.03
Current: 44.72
44.72
75.03
Days Sales Outstanding 53.08
ENZ's Days Sales Outstanding is ranked higher than
63% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ENZ: 53.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.29  Med: 50.46 Max: 99.02
Current: 53.08
45.29
99.02
Days Payable 64.41
ENZ's Days Payable is ranked higher than
58% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ENZ: 64.41 )
Ranked among companies with meaningful Days Payable only.
ENZ' s Days Payable Range Over the Past 10 Years
Min: 29.18  Med: 55.95 Max: 64.59
Current: 64.41
29.18
64.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ENZ's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ENZ: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.3  Med: -1.5 Max: -0.4
Current: -4.5
-24.3
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.05
ENZ's Price-to-Net-Cash is ranked higher than
62% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. ENZ: 9.05 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZ' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.26  Med: 8.92 Max: 737
Current: 9.05
3.26
737
Price-to-Net-Current-Asset-Value 5.85
ENZ's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ENZ: 5.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.37  Med: 5.92 Max: 198.33
Current: 5.85
2.37
198.33
Price-to-Tangible-Book 5.18
ENZ's Price-to-Tangible-Book is ranked higher than
52% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ENZ: 5.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.56  Med: 4.87 Max: 124.5
Current: 5.18
1.56
124.5
Price-to-Intrinsic-Value-Projected-FCF 4.24
ENZ's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
71% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ENZ: 4.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENZ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.82  Med: 3.99 Max: 410
Current: 4.24
1.82
410
Price-to-Median-PS-Value 1.85
ENZ's Price-to-Median-PS-Value is ranked lower than
88% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ENZ: 1.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 3.08 Max: 22.57
Current: 1.85
0.18
22.57
Price-to-Peter-Lynch-Fair-Value 2.87
ENZ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. ENZ: 2.87 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ENZ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.57  Med: 2.14 Max: 6.81
Current: 2.87
1.57
6.81
Price-to-Graham-Number 1.72
ENZ's Price-to-Graham-Number is ranked higher than
72% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. ENZ: 1.72 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ENZ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.03  Med: 4.63 Max: 21.06
Current: 1.72
1.03
21.06
Earnings Yield (Greenblatt) % 10.31
ENZ's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ENZ: 10.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 10.65 Max: 27.4
Current: 10.31
3.1
27.4
Forward Rate of Return (Yacktman) % 32.85
ENZ's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. ENZ: 32.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENZ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -31.2  Med: -4.7 Max: 32.85
Current: 32.85
-31.2
32.85

More Statistics

Revenue (TTM) (Mil) $105.6
EPS (TTM) $ 0.67
Beta1.51
Short Percentage of Float1.81%
52-Week Range $4.76 - 8.98
Shares Outstanding (Mil)46.29

Analyst Estimate

Jul17
Revenue (Mil $)
EPS ($) -0.15
EPS without NRI ($) -0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Is the S&P 500 the Right Portfolio for You? Apr 03 2017 
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 

More From Other Websites
ETFs with exposure to Enzo Biochem, Inc. : April 17, 2017 Apr 17 2017
Enzo Biochem’s Clinical Laboratory Named an In-Network Provider to the Fourth Largest National... Apr 17 2017
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe Apr 13 2017
Amedisys (AMED) Poised on Strong Home Health, Risks Remain Apr 05 2017
QIAGEN Releases Favorable GeneReader Results, Expands in NGS Apr 04 2017
Enzo Biochem Stock: 3 Reasons Why ENZ Is a Top Choice for Momentum Investors Apr 04 2017
Earnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy? Mar 27 2017
Enzo Biochem (ENZ) Shares March Higher, Can It Continue? Mar 24 2017
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017 Mar 22 2017
Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2% Mar 21 2017
Enzo Biochem reports 2Q loss Mar 13 2017
Enzo Biochem Reports Increased Second Quarter Operating Results Mar 13 2017
Enzo Biochem Re-Schedules Teleconference to Discuss Second Quarter 2017 Results for This Afternoon,... Mar 13 2017
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2017 Results Tuesday, March 14, 2017... Mar 06 2017
Enzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : March 6, 2017 Mar 06 2017
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View Feb 09 2017
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales Feb 03 2017
Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study Jan 27 2017
Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher Jan 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)